Search research articles
Contact Us
Filters
Showing results (261-270 of 333) with videos related to
Page
of 34
Sort By:
Clinics in Liver Disease
|
April 6, 2023
Research Priorities for Precision Medicine in NAFLD
Paula Iruzubieta, Ramon Bataller, María Teresa Arias-Loste, et al.
Alimentary Pharmacology & Therapeutics
|
February 19, 2025
Addressing the High and Rising Global Burden of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) and Metabolic Dysfunction-Associated Steatohepatitis (MASH): From the Growing Prevalence to Payors' Perspective
Zobair M Younossi, Homie Razavi, Michael Sherman, et al.
Liver International : Official Journal of the International Association for the Study of the Liver
|
March 19, 2026
Care Pathways for Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): A State-of-The-Art Review
Kirsi M A van Eekhout, Leonard D Broekman, Vivian D de Jong, et al.
Gastroenterology
|
June 15, 2026
Validated early detection metrics reduce the population requiring liver fibrosis screening
Laurens A van Kleef, Jesse Pustjens, Carolin V Schneider, et al.
Journal of Hepatology
|
December 31, 2019
A randomized, placebo-controlled trial of emricasan in patients with NASH and F1-F3 fibrosis
Stephen A Harrison, Zachary Goodman, Abdul Jabbar, et al.
JHEP Reports : Innovation in Hepatology
|
January 24, 2022
Increased serum miR-193a-5p during non-alcoholic fatty liver disease progression: Diagnostic and mechanistic relevance
Katherine Johnson, Peter J Leary, Olivier Govaere, et al.
Journal of Hepatology
|
August 28, 2022
Long-term persistence of HCV resistance-associated substitutions after DAA treatment failure
Julia Dietz, Beat Müllhaupt, Peter Buggisch, et al.
Hepatology Communications
|
December 2, 2024
Serum protein risk stratification score for diagnostic evaluation of metabolic dysfunction-associated steatohepatitis
Michelle Lai, Simon T Dillon, Xuesong Gu, et al.
British Journal of Clinical Pharmacology
|
December 9, 2025
Effects of zibotentan and dapagliflozin combined in patients with compensated cirrhosis: A randomized placebo-controlled exploratory study
Juan Carlos Garcia-Pagan, Lise Lotte Gluud, Mattias Mandorfer, et al.
Alimentary Pharmacology & Therapeutics
|
December 6, 2021
A sustainable development goal framework to guide multisectoral action on NAFLD through a societal approach
Jeffrey V Lazarus, Henry E Mark, Massimo Colombo, et al.
Page
of 34
Search research articles
Search
Showing results (261-270 of 333) with videos related to
Sort By:
Page
of 34
Clinics in Liver Disease
|
April 6, 2023
Research Priorities for Precision Medicine in NAFLD
Paula Iruzubieta, Ramon Bataller, María Teresa Arias-Loste, et al.
Alimentary Pharmacology & Therapeutics
|
February 19, 2025
Addressing the High and Rising Global Burden of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) and Metabolic Dysfunction-Associated Steatohepatitis (MASH): From the Growing Prevalence to Payors' Perspective
Zobair M Younossi, Homie Razavi, Michael Sherman, et al.
Liver International : Official Journal of the International Association for the Study of the Liver
|
March 19, 2026
Care Pathways for Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): A State-of-The-Art Review
Kirsi M A van Eekhout, Leonard D Broekman, Vivian D de Jong, et al.
Gastroenterology
|
June 15, 2026
Validated early detection metrics reduce the population requiring liver fibrosis screening
Laurens A van Kleef, Jesse Pustjens, Carolin V Schneider, et al.
Journal of Hepatology
|
December 31, 2019
A randomized, placebo-controlled trial of emricasan in patients with NASH and F1-F3 fibrosis
Stephen A Harrison, Zachary Goodman, Abdul Jabbar, et al.
JHEP Reports : Innovation in Hepatology
|
January 24, 2022
Increased serum miR-193a-5p during non-alcoholic fatty liver disease progression: Diagnostic and mechanistic relevance
Katherine Johnson, Peter J Leary, Olivier Govaere, et al.
Journal of Hepatology
|
August 28, 2022
Long-term persistence of HCV resistance-associated substitutions after DAA treatment failure
Julia Dietz, Beat Müllhaupt, Peter Buggisch, et al.
Hepatology Communications
|
December 2, 2024
Serum protein risk stratification score for diagnostic evaluation of metabolic dysfunction-associated steatohepatitis
Michelle Lai, Simon T Dillon, Xuesong Gu, et al.
British Journal of Clinical Pharmacology
|
December 9, 2025
Effects of zibotentan and dapagliflozin combined in patients with compensated cirrhosis: A randomized placebo-controlled exploratory study
Juan Carlos Garcia-Pagan, Lise Lotte Gluud, Mattias Mandorfer, et al.
Alimentary Pharmacology & Therapeutics
|
December 6, 2021
A sustainable development goal framework to guide multisectoral action on NAFLD through a societal approach
Jeffrey V Lazarus, Henry E Mark, Massimo Colombo, et al.
Page
of 34